Hereditary Angioedema Treatment Market – Global Industry Analysis, Size, Share, Growth, Current Demand, and Development Report

TMR’s report on the global hereditary angioedema treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global hereditary angioedema treatment market for the period of 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global hereditary angioedema treatment market for the forecast period.

The report has been prepared after extensive primary and secondary research. Primary research involved bulk of the research efforts, wherein, analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global hereditary angioedema treatment market.

Request Brochure for Report –

Global Hereditary Angioedema Treatment market Witness Most Promising Rise in Demand

In recent years, there has been an impressive amount of research being done for the development of drugs for hereditary angioedema treatment. This has included not just drugs to control the symptoms of the illness, but also prophylactic treatment for HAE attacks. There are currently several drugs that are in various stages of approval for the long-term prophylactic treatment of HAE in children and adults. For instance, in May 2019, BioCryst Pharmaceuticals announced that its drug – BCX7353, for the prevention of (HAE) attacks, has achieved its primary endpoint for both dose levels.

Request for Analysis of COVID19 Impact on Hereditary Angioedema Treatment Market –

The global hereditary angioedema treatment market was valued at ~US$ 2 Bn in 2018.

The global hereditary angioedema treatment market is projected to reach a value of ~US$ 5 Bn by 2027, expanding at a CAGR of ~9% from 2019 to 2027.

 Key Players of Hereditary Angioedema Treatment Market Report:

Key players analyzed in this report on the global hereditary angioedema treatment market are Shire plc (Takeda Pharmaceutical Company Limited), CSL Limited, and Pharming Group NV. This section also includes companies such as Ionis Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., KalVista Pharmaceuticals Ltd., and Attune Pharmaceuticals that have drugs in the pipeline, which are expected to launch in the new few years.

Robust R&D activities for pipeline products, new product approvals for specific indications, and strategic mergers & acquisitions are the key strategies adopted by major players in the global hereditary angioedema treatment market.

 Buy Hereditary Angioedema Treatment Market Report –

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.


Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453